Eisai Aktie
29,86EUR | 0,45EUR | 1,53% |
WKN: 855526 / ISIN: JP3160400002
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 83,82 |
Vanguard Health Care Fund | 6,45 |
Eisai Co., Ltd. | 4,87 |
Government of Japan | 3,76 |
Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 3,01 |
Nikko Asset Management Co., Ltd. | 2,84 |
Sumitomo Mitsui Trust Asset Management Co., Ltd. | 2,67 |
Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 2,63 |
Nippon Life Insurance Co. | 2,19 |
American Funds EuroPacific Growth Fund | 2,14 |
Nikko Exchange Traded Index Fund 225 | 1,45 |
Resona Holdings, Inc. | 1,45 |
The Naito Foundation | 1,42 |
Tokio Marine Holdings, Inc. | 0,58 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 10 998 | 11 237 | 11 322 | 11 076 | 11 067 |
Umsatz pro Mitarbeiter in Mio. EUR | 63,25 | 57,48 | 66,79 | 67,21 | 67,02 |
Bilanz (in Mio. JPY) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 520 837 | 517 886 | 640 260 | 621 847 | 722 237 |
Summe Anlagevermögen | 541 303 | 572 123 | 599 055 | 641 503 | 671 562 |
Summe Aktiva | 1 062 140 | 1 090 009 | 1 239 315 | 1 263 350 | 1 393 799 |
Bilanz (in Mio. JPY) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 89 939 | 138 633 | 143 032 | 170 918 | 206 746 |
Summe Fremdkapital | 359 509 | 362 067 | 467 781 | 440 779 | 494 825 |
Summe Eigenkapital | 702 630 | 727 942 | 771 533 | 822 571 | 898 975 |
Summe Passiva | 1 062 139 | 1 090 009 | 1 239 314 | 1 263 350 | 1 393 800 |
Adresse
4-6-10 Koishikawa, 112-8088 Tokyo | |
Telefon | +81 (3) 3817-3030 |
Internet | http://www.eisai.co.jp |
Management
Akiko Nakahama
Chief Portfolio Officer & Regulatory Affairs |
Clive Richard Thornley
Independent Outside Director |
Fumihiko Ike
Independent Outside Director |
Gary Bryan Hendler
Managing Executive Officer & President-EMEA |
Haruo Naito
Chief Executive Officer & Director |
Hiroyuki Kato
Director |
Kanai Sawaji
Independent Outside Director |
Keisuke Naito
Executive VP, Chief Operating & Growth Officer |
Kenta Takahashi
Director |
Lynn D. Kramer
Chief Clinical Officer & Vice President |
Makoto Hoketsu
Chief Information Officer |
Masatomi Akana
SVP, Chief Government & Investor Relations Officer |
Mitsuru Shomon
Chief Financial Officer & Head-Accounting |
Ryota Miura
Independent Outside Director |
Sayoko Sasaki
Vice President-Communications & Sustainability |
Shin Kato
Chief Compliance Officer, VP & General Counsel |
Shin Ujiie
Director-Strategy Officer |
Shinichi Sagawa
Head-Finance & Accounting |
Shohei Kanazawa
President-Asia & Latin America Region |
Takashi Owa
Chief Scientific Officer & Senior Vice President |
Terushige Iike
Executive VP, Chief Strategy & Planning Officer |
Teruyuki Masaka
Executive Officer & Chief Human Resources Officer |
Toru Moriyama
Independent Outside Director |
Toshitaka Asano
Executive Officer & Head-Business Development |
Yan Hui Feng
Senior Vice President |
Yasushi Okada
Head-Industry Affairs & Internal Audit |
Yoshiteru Kato
Director |
Yuko Yasuda
Independent Outside Director |
Yumiko Miwa
Independent Outside Director |